Key Takeaways

  • The phase 2 trial of BL1332 did not meet its primary endpoint but demonstrated consistent numerical improvements in post-PRK pain relief versus vehicle

  • Exploratory analyses suggested higher rates of complete pain relief and potentially faster corneal epithelial healing among BL1332-treated patients

  • Bausch + Lomb plans to discuss the findings and potential phase 3 development with the FDA

Bausch + Lomb announced topline results from a phase 2 clinical trial evaluating BL1332, a first-in-class topical TRPV1 antagonist, in patients experiencing ocular pain following photorefractive keratectomy (PRK) surgery. The study did not meet its primary endpoint, however both treatment groups demonstrated numerical improvements in pain relief compared with vehicle.

The randomized, double-masked, vehicle-controlled study enrolled 129 adults undergoing unilateral sequential PRK for myopia. Participants received BL1332 0.30%, BL1332 0.15%, or vehicle in a 2:2:1 ratio, with treatment initiated immediately after surgery and follow-up through day 14.

The study failed to demonstrate a statistically significant improvement in the primary endpoint of summed pain intensity differences (SPID) over 24 hours. However, both doses consistently favored BL1332 across pain assessments through 72 hours. The 0.30% dose also demonstrated a nominally significant reduction in pain during the first 6 hours after surgery. At 6 hours, complete pain relief was reported by 14% of patients receiving BL1332 0.30%, and 14.6% receiving BL1332 0.15%, compared with 3.7% receiving vehicle.

Exploratory anterior segment OCT findings showed greater central corneal epithelial thickness at day 3 in both treatment groups, suggesting potentially faster corneal healing.

BL1332 was generally well tolerated, with treatment-emergent adverse events reported in 6%, 13.7%, and 14.8% of patients in the 0.30%, 0.15%, and vehicle groups, respectively. No treatment-related adverse events, serious adverse events, or adverse event-related discontinuations occurred.

“What stands out from this study is the consistency of the findings,” said Yehia Hashad, MD, executive vice president, R&D and chief medical officer, Bausch + Lomb. “Both dose groups showed numerically greater pain relief than vehicle across all the pain measures we evaluated, more patients achieved complete pain relief following surgery and we observed evidence of faster corneal healing. These findings help define the clinical profile of BL1332 and will inform our discussions with the FDA on next steps, including potential phase 3 planning.”